Europe Induced Pluripotent Stem Cells Market Size & Outlook
Europe induced pluripotent stem cells market, 2018-2030 (US$M)
Related Markets
Europe induced pluripotent stem cells market highlights
- The Europe induced pluripotent stem cells market generated a revenue of USD 404.4 million in 2022.
- The market is expected to grow at a CAGR of 10.3% from 2023 to 2030.
- In terms of segment, fibroblasts was the largest revenue generating derived cell type in 2022.
- Hepatocytes is the most lucrative derived cell type segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 404.4 million |
| Market revenue in 2030 | USD 889.1 million |
| Growth rate | 10.3% (CAGR from 2022 to 2030) |
| Largest segment | Fibroblasts |
| Fastest growing segment | Hepatocytes |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells |
| Key market players worldwide | Lonza Group Ltd, Axol Bioscience, Evotec SE, Hitachi Ltd, ReproCELL, Merck KGaA, Fate Therapeutics Inc, Thermo Fisher Scientific Inc, Stemcell Holdings Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.9% of the global induced pluripotent stem cells market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 607.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Induced Pluripotent Stem Cells Market Scope
Induced Pluripotent Stem Cells Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe induced pluripotent stem cells market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to induced pluripotent stem cells market will help companies and investors design strategic landscapes.
Fibroblasts was the largest segment with a revenue share of 30.46% in 2022. Horizon Databook has segmented the Europe induced pluripotent stem cells market based on hepatocytes, fibroblasts, keratinocytes, amniotic cells covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe induced pluripotent stem cells market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe induced pluripotent stem cells market databook
-
Our clientele includes a mix of induced pluripotent stem cells market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe induced pluripotent stem cells market, including forecasts for subscribers. This continent databook contains high-level insights into Europe induced pluripotent stem cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe induced pluripotent stem cells market report size, by country, 2018-2030 (US$M)
Europe Induced Pluripotent Stem Cells Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
